Christopher Fennell, DO
Psychiatry · Maysville, KYNPI 1437133535
Payments from drug & device makers
Across 114 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$667
- Alkermes, Inc.$268
- Axsome Therapeutics, Inc.$235
- Lundbeck LLC$182
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$126
- Otsuka America Pharmaceutical, Inc.$117
- plus $426 from 15 others
What the payments were for
- Food & beverage$2,021100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $667 |
| Alkermes, Inc. | 13 | $268 |
| Axsome Therapeutics, Inc. | 12 | $235 |
| Lundbeck LLC | 11 | $182 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $126 |
| Otsuka America Pharmaceutical, Inc. | 6 | $117 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Indivior Inc. | 2 | $56 |
| Sunovion Pharmaceuticals Inc. | 3 | $49 |
| Johnson & Johnson | 3 | $49 |
| Ironshore Pharmaceuticals Inc. | 2 | $31 |
| Novo Nordisk | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Merck | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
How this compares
$2,021 in reported general payments places this provider in the 75th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 84 | $127,903 |
| Invega SustennaPaliperidone Palmitate | 13 | $37,524 |
| AuvelityDextromethorphan Hbr/Bupropion | 23 | $24,856 |
| TrintellixVortioxetine Hydrobromide | 40 | $18,836 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $16,392 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 136 | $9,856 |
| Lurasidone Hcl | 42 | $8,331 |
| FetzimaLevomilnacipran Hcl | 12 | $6,761 |
| Bromocriptine Mesylate | 22 | $6,358 |
| Vilazodone Hcl | 76 | $5,732 |
| Paliperidone ErPaliperidone | 17 | $5,333 |
| KlonopinClonazepam | 15 | $4,439 |
| Atomoxetine Hcl | 18 | $3,883 |
| Aripiprazole | 61 | $3,753 |
| Quetiapine Fumarate | 181 | $3,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $667 | $134,66496 claims |
| Johnson & JohnsonInvega Sustenna | $49 | $37,52413 claims |
| Axsome Therapeutics, Inc.Auvelity | $235 | $24,85623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $20 | $18,83640 claims |
| Alkermes, Inc.Lybalvi | $268 | $16,39211 claims |
| Lilly USA, LLCOlanzapine | $18 | $1,13554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Maysville
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.7M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Balakumar KrishnaswamyHazard$162K
- Steven CroleyLexington$151K
- Joseph HarrisonOwensboro$131K
- Stephanie HallLouisville$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.